Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Post-exposure treatment of VX poisoned guinea pigs with the engineered phosphotriesterase mutant C23: a proof-of-concept study.

Toxicology letters - 18 Nov 2014

Worek Franz, Seeger Thomas, Reiter Georg, Goldsmith Moshe, Ashani Yacov, Leader Haim, Sussman Joel L, Aggarwal Nidhi, Thiermann Horst, Tawfik Dan S

Abstract excerpt

The highly toxic organophosphorus (OP) nerve agent VX is characterized by a remarkable biological persistence which limits the effectiveness of standard treatment with atropine and oximes. Existing OP hydrolyzing enzymes show low activity against VX and hydrolyze preferentially the less toxic P(+)-VX enantiomer. Recently, a phosphotriesterase (PTE) mutant, C23, was engineered towards the hydrolysis of the toxic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcholinesterase
Share to Cholinesterase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Erythrocytes

Share to Guinea Pigs

Share to Hydrolysis

Share to Neurotoxicity Syndromes

Share to Protein Engineering

Source

Identifiers

PMID: 25195526
DOI: 10.1016/j.toxlet.2014.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Post-exposure treatment of VX poisoned guinea pigs with the engineered phosphotriesterase mutant C23: a proof-of-concept study.PMID 25195526Read ↗

Single treatment of VX poisoned guinea pigs with the phosphotriesterase mutant C23AL: Intraosseous versus intravenous injection.Semantic proximity Read ↗

Catalytic efficiencies of directly evolved phosphotriesterase variants with structurally different organophosphorus compounds in vitro.Semantic proximity Read ↗

Variants of Phosphotriesterase for the Enhanced Detoxification of the Chemical Warfare Agent VR.Semantic proximity Read ↗

Catalytic activity and stereoselectivity of engineered phosphotriesterases towards structurally different nerve agents in vitro.Semantic proximity Read ↗

Computational Design of Phosphotriesterase Improves V-Agent Degradation Efficiency.Semantic proximity Read ↗

Organophosphate hydrolases as catalytic bioscavengers of organophosphorus nerve agents.Semantic proximity Read ↗

Identification of human butyrylcholinesterase organophosphate-resistant variants through a novel mammalian enzyme functional screen.Semantic proximity Read ↗

Investigation of evolved paraoxonase-1 variants for prevention of organophosphorous pesticide compound intoxication.Semantic proximity Read ↗

Rational design of organophosphorus hydrolase with high catalytic efficiency for detoxifying a V-type nerve agent.Semantic proximity Read ↗

Phosphotriesterase variants with high methylphosphonatase activity and strong negative trade-off against phosphotriesters.Semantic proximity Read ↗

Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning.Semantic proximity Read ↗

Enzymes for the homeland defense: optimizing phosphotriesterase for the hydrolysis of organophosphate nerve agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.